Oppenheimer downgraded shares of Vericel (NASDAQ:VCEL) from an outperform rating to a market perform rating in a report issued on Monday, Analyst Ratings Network reports.
A number of other equities analysts also recently commented on the stock. SVB Leerink upped their target price on shares of Vericel from $20.00 to $30.00 and gave the stock an outperform rating in a research note on Monday, October 12th. Zacks Investment Research downgraded shares of Vericel from a buy rating to a hold rating in a research note on Saturday, January 9th. ValuEngine downgraded shares of Vericel from a buy rating to a hold rating in a research note on Tuesday, December 1st. HC Wainwright upped their target price on shares of Vericel from $22.00 to $26.00 and gave the stock a buy rating in a research note on Thursday, October 15th. Finally, BTIG Research upped their target price on shares of Vericel from $30.00 to $37.00 and gave the stock a buy rating in a research note on Tuesday, January 5th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Vericel has an average rating of Buy and a consensus target price of $29.75.
Shares of NASDAQ:VCEL opened at $36.92 on Monday. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -3,692.00 and a beta of 2.73. Vericel has a 12 month low of $6.78 and a 12 month high of $37.98. The firm’s 50-day moving average is $28.53 and its 200 day moving average is $20.85.
In other news, Director Robert L. Md Zerbe sold 17,500 shares of the company’s stock in a transaction that occurred on Monday, November 23rd. The shares were sold at an average price of $23.55, for a total value of $412,125.00. Following the completion of the sale, the director now owns 34,295 shares of the company’s stock, valued at approximately $807,647.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the stock. Iron Triangle Partners LP purchased a new position in shares of Vericel in the third quarter worth $10,747,000. Scout Investments Inc. purchased a new position in shares of Vericel in the third quarter worth $6,842,000. Perkins Capital Management Inc. purchased a new position in shares of Vericel in the third quarter worth $5,131,000. Federated Hermes Inc. raised its holdings in shares of Vericel by 17.8% in the third quarter. Federated Hermes Inc. now owns 1,325,112 shares of the biotechnology company’s stock worth $24,554,000 after buying an additional 200,600 shares during the last quarter. Finally, Summit Creek Advisors LLC increased its stake in shares of Vericel by 34.7% in the third quarter. Summit Creek Advisors LLC now owns 636,164 shares of the biotechnology company’s stock worth $11,788,000 after acquiring an additional 163,822 shares during the period. 94.98% of the stock is owned by institutional investors.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Featured Story: How mutual funds make money
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.